Structure Therapeutics (NASDAQ: GPCR) CEO awarded new options and 260,217 RSUs

Rhea-AI Filing Summary

Structure Therapeutics Inc.’s CEO, Raymond C. Stevens, received new equity awards. On March 19, 2026, he was granted an option to buy 322,230 Ordinary Shares at an exercise price of $16.82 per share, expiring on March 18, 2036.

He also received 260,217 restricted stock units, each representing one Ordinary Share, vesting one-quarter annually on each anniversary of March 1, 2026, subject to continued service. Following these grants, he holds 1,401,593 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through the Stevens 2001 Revocable Trust. Each American Depositary Share represents three Ordinary Shares.

Insights

Equity compensation analyst

CEO receives sizable but routine stock option and RSU grants as compensation.

CEO Raymond C. Stevens was granted options over 322,230 Ordinary Shares at $16.82 per share plus 260,217 RSUs. These are compensation awards, not open-market purchases or sales, so they carry limited signaling value for near-term trading sentiment.

The option starts vesting on March 1, 2027 with remaining vesting over 36 monthly installments, while RSUs vest in four annual tranches from March 1, 2026. The filing also confirms substantial existing holdings, both direct and via the Stevens 2001 Revocable Trust, underscoring long-term equity exposure rather than a change in stance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stevens Raymond C

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/19/2026		A(2)		260,217	A	$0	1,401,593	D
Ordinary Shares(1)								1,554,586	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$16.82(4)	03/19/2026		A		322,230		(5)	03/18/2036	Ordinary Shares(1)	322,230	$0	322,230	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.

3. By Raymond Stevens and Vivian Urena-Stevens, as Co-Trustees of the Stevens 2001 Revocable Trust, dated March 28, 2001.

4. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

5. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Jun Yoon, Attorney-in-Fact	03/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did GPCR CEO Raymond C. Stevens receive in this Form 4?

Raymond C. Stevens received an option over 322,230 Ordinary Shares at an exercise price of $16.82 per share and 260,217 restricted stock units, each representing one Ordinary Share, as part of his equity compensation package on March 19, 2026.

How do the new stock options for GPCR’s CEO vest and when do they expire?

The option vests 25% on March 1, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to continued service. The option expires on March 18, 2036, giving a long-dated incentive tied to Structure Therapeutics’ share performance.

What is the vesting schedule for the 260,217 RSUs granted to GPCR’s CEO?

The 260,217 RSUs each convert into one Ordinary Share. They vest one-quarter annually on each anniversary of March 1, 2026, provided Raymond C. Stevens continues his service. This creates a four-year vesting horizon aligned with retention and long-term performance.

How many Structure Therapeutics shares does the CEO hold after these transactions?

After the grants, Raymond C. Stevens holds 1,401,593 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through the Stevens 2001 Revocable Trust. These positions reflect substantial ongoing ownership alongside the newly awarded options and RSUs reported in the Form 4.

Are Structure Therapeutics Ordinary Shares represented by ADSs for GPCR investors?

Yes. Each American Depositary Share (ADS) of Structure Therapeutics represents three Ordinary Shares. The Form 4 clarifies that the option and RSU awards relate to Ordinary Shares, which may be represented in the market through ADSs at this three-to-one ratio.

Does this GPCR Form 4 show open-market buying or selling by the CEO?

No. The filing shows grants of an employee stock option and RSUs to the CEO, both at a transaction price of $0.00 per share. These are compensation-related awards, not open-market purchases or sales, so they mainly affect his incentive structure and ownership.